Skip to main content

TNBC: immunotherapy in the neoadjuvant setting

Intervista a Leisha A. Emens By 30 Novembre 2023No Comments
Congressi

A subset of triple negative breast cancer is immune activated, suggesting that immunotherapy may be a viable treatment strategy in both early and advanced TNBC. High priorities for the field include developing more active immunotherapy combination regimens and more refined biomarkers that optimally identify patients most likely to benefit from immunotherapy. Leisha A. Emens (Senior vice president, translational research Ankyra Therapeutics, President of Society for Immunotherapy of Cancer’s – SITC) gave us an overview of the topic at the Immunotherapy Bridge congress 2023 in Naples.